BioCrossroads has named Eli Lilly CEO, Dave Ricks, the recipient of the 2024 August M. Watanabe Life Sciences Champion of the ...

Nvidia topping Apple as the most valuable company in the world and joining the Dow Jones Industrial Average. Why Novo Nordisk and Eli Lilly are giving totally different reads on the markets for GLP-1 ...

The Eli Lilly (NYSE:LLY) share price fell by double digits in the S&P 500 today, leaving this Fool debating whether he should ...

Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two key drugs that missed expectations. The drugmaker ...

Skyrocketing demand for weight loss and diabetes drugs has forced Eli Lilly and Novo Nordisk, to invest billions to increase ...

CHICAGO, Oct 29 (Reuters) - Starting on a more gradual dosing schedule of Eli Lilly's (LLY.N), opens new tab Alzheimer's drug Kisunla cut the percentage of patients experiencing potentially ...

NEW YORK (AP) — U.S. stock indexes are wavering Wednesday following a strong profit report from Google’s parent company, while drops for Eli Lilly and others are keeping Wall Street in check.

In this article, we are going to take a look at where Eli Lilly And Co. (NYSE:LLY) stands against other stocks to buy before they split next. There’s been a notable sense of fear among investors ...

A change in the dosing regimen of Eli Lilly’s Alzheimer’s drug Kisunla resulted in a lower rate of brain swelling among patients in a clinical trial, new data reported Tuesday show.

Paulo Nunes dos Santos / Bloomberg via Getty Images Eli Lilly will report third-quarter earnings Wednesday morning, with the focus remaining on the production and sales of its popular weight-loss ...

Those who follow my work closely know that I have been a big fan of pharmaceutical firm Eli Lilly and Company (NYSE ... across the board. Management certainly seems optimistic that growth for ...

Key drugs from Johnson & Johnson and Eli Lilly stand to bolster their respective cases in competitive dermatology markets with new data readouts. J&J evaluated its Tremfya in patients with low ...